Phathom Pharmaceuticals annual free cash flow per share
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Free Cash Flow Per Share Growth & History (PHAT)
Phathom Pharmaceuticals's free cash flow per share was -$2.29 for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$2.29 | $1.93 | — |
| 2024 | 2024-12-31 | -$4.22 | -$1.51 | — |
| 2023 | 2023-12-31 | -$2.71 | $1.06 | — |
| 2022 | 2022-12-31 | -$3.77 | $0.25 | — |
| 2021 | 2021-12-31 | -$4.02 | -$1.89 | — |
| 2020 | 2020-12-31 | -$2.13 | $1.10 | — |
| 2019 | 2019-12-31 | -$3.22 | — | — |
Phathom Pharmaceuticals quarterly free cash flow per share
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.02 | $0.84 | — |
| Q1 2026 | 2026-03-31 | -$0.19 | $0.99 | — |
| Q4 2025 | 2025-12-31 | -$0.07 | — | — |
| Q3 2025 | 2025-09-30 | -$0.19 | $0.79 | — |
| Q2 2025 | 2025-06-30 | -$0.87 | $0.34 | — |
| Q1 2025 | 2025-03-31 | -$1.18 | $0.00 | — |
| Q3 2024 | 2024-09-30 | -$0.98 | -$0.41 | — |
| Q2 2024 | 2024-06-30 | -$1.21 | -$0.75 | — |
| Q1 2024 | 2024-03-31 | -$1.18 | -$0.24 | — |
| Q3 2023 | 2023-09-30 | -$0.58 | $0.33 | — |
| Q2 2023 | 2023-06-30 | -$0.46 | $0.23 | — |
| Q1 2023 | 2023-03-31 | -$0.94 | $0.24 | — |
| Q3 2022 | 2022-09-30 | -$0.91 | -$0.13 | — |
| Q2 2022 | 2022-06-30 | -$0.68 | $0.09 | — |
| Q1 2022 | 2022-03-31 | -$1.18 | $0.20 | — |
| Q3 2021 | 2021-09-30 | -$0.78 | -$0.15 | — |
| Q2 2021 | 2021-06-30 | -$0.78 | -$0.49 | — |
| Q1 2021 | 2021-03-31 | -$1.38 | -$1.00 | — |
| Q4 2020 | 2020-12-31 | -$0.83 | — | — |
| Q3 2020 | 2020-09-30 | -$0.63 | — | — |
| Q2 2020 | 2020-06-30 | -$0.28 | — | — |
| Q1 2020 | 2020-03-31 | -$0.37 | — | — |
Phathom Pharmaceuticals free cash flow per share trends
Over the last five fiscal years, Phathom Pharmaceuticals's free cash flow per share decreased from -$2.13 to -$2.29, a change of -$0.16. The latest reported quarter, Q2 2026, shows -$0.02.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
